Editorial: Long Term Follow-Up of Visual Acuity After anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration

Abstract

Long term follow-up of visual acuity in macular degeneration represents an important issue in the management of elderly population. Previous study on macular photocoagulation could demonstrate after five years of follow-up untreated eyes had a mean visual loss of 7.1 lines, while laser treated eyes had lost 5.2 lines [1]. Most clinical studies on anti-VEGF therapies have a follow-up of 24 months such as ANCHOR study or MARINA study [1], [2]. More recently Long term efficacy of therapy was evaluated in SEVENUP study considering outcome evolution of ANCHOR, MARINA and HORIZON study [3], [4]. Bevacizumab and ranibizumab in a monthly protocol had also the same visual outcome in the CATT study in a monthly regimen [5]. This could also be confirmed at one year in a treat and extend protocol [6].